Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
Ciena Slides On Lower Profit, Revenue Below Estimates In Q3
-
Markets React To The Jobs Data, War Clouds
-
Zymeworks Up 10% On Positive Study Results Of Zanidatamab In Biliary Tract Cancer Treatment
-
Berkshire Hathaway’s Vice Chairman Slams Bitcoin and Cryptocurrencies as Worthless and Stupid
-
Why Spot Bitcoin ETF Approval Odds Just Shot Up, According To Bloomberg